Clinical Guides
Chronic Obstructive Pulmonary Disease
A clinically focused guide to confirming, phenotyping and managing chronic obstructive pulmonary disease in Indian practice, including tobacco, household-air-pollution and post-tuberculosis contexts, exacerbations, respiratory failure, comorbidity and limits of guideline transfer.
MedNext Academy | 13 min read
Chronic Obstructive Pulmonary Disease
A clinically focused guide to confirming, phenotyping and managing chronic obstructive pulmonary disease in Indian practice, including tobacco, household-air-pollution and post-tuberculosis contexts, exacerbations, respiratory failure, comorbidity and limits of guideline transfer.
Summary
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterised by persistent respiratory symptoms and airflow obstruction arising from airway and alveolar abnormalities. Chronic cough, sputum, exertional breathlessness, wheeze, recurrent lower-respiratory events and loss of activity may occur in different combinations. Tobacco is an important cause, but a smoking history is not compulsory: household biomass smoke, ambient and occupational pollution, impaired lung growth, previous infections and alpha-1 antitrypsin deficiency can contribute. In India, assuming that COPD is a disease only of older male smokers misses exposed women and people with post-tuberculosis structural lung damage.
COPD is suspected clinically but confirmed by good-quality post-bronchodilator spirometry in the appropriate context. A fixed FEV1/FVC ratio below 0.70 is the GOLD criterion, while age, test quality and the lower limit of normal help interpret borderline results. Spirometric grade alone does not describe the person. Symptom burden, exacerbation history, blood eosinophils, oxygenation, functional capacity, inhaler technique, exposure, multimorbidity and the patient's priorities guide treatment.
Management combines exposure cessation, vaccination, physical activity and pulmonary rehabilitation with individually selected inhaled bronchodilators. Inhaled corticosteroids are not universal COPD treatment and require a benefit-risk discussion. Exacerbations demand assessment for mimics, controlled oxygen when indicated and escalation for ventilatory failure. Advanced disease requires anticipatory planning, symptom relief and palliative care alongside disease-directed care; this educational draft cannot replace locally supervised prescribing or respiratory review.
How Common Is It?
COPD is a major cause of death and disability worldwide, but measured prevalence depends on age, exposure, whether spirometry was used and which threshold defined obstruction. WHO reported in June 2026 that COPD caused 3.4 million deaths in 2023 and that nearly 90% of deaths before age 70 occurred in low- and middle-income countries. These are global estimates, not a current Indian prevalence or an individual's prognosis. Studies based on symptoms or physician labels usually miss undiagnosed disease, whereas surveys using a fixed spirometric ratio may overclassify some older adults and underrecognise younger adults with abnormal lung trajectories.
The Indian burden is shaped by overlapping exposures. Cigarettes, bidis and other tobacco products remain important; household smoke from wood, dung, crop residues or coal can affect people who cook or remain near poorly ventilated fires; construction, mining, stone cutting, agriculture and manufacturing can entail dusts, fumes and chemicals. Ambient pollution may worsen symptoms and exacerbations. Tuberculosis is common enough that healed or active TB, bronchiectasis and destroyed-lung patterns belong in the differential rather than being automatically folded into COPD.
Burden is also social. Breathlessness may limit employment, caregiving, travel and medication collection before a person seeks care. Spirometry, trained interpretation, long-acting inhalers and pulmonary rehabilitation are unevenly accessible. Population numbers therefore should not be used to imply that every exposed person has COPD. Case finding is most useful among people with compatible symptoms or imaging findings, followed by diagnostic-quality spirometry rather than indiscriminate screening of asymptomatic adults.
Risk Factors
Take an exposure and life-course history, not only a pack-year total. Record current and past cigarettes, bidis, hookah, smokeless tobacco and second-hand smoke; duration, intensity, periods of abstinence and readiness to quit matter. Ask who cooks, which fuel is used, whether the stove is indoors, the degree of ventilation and whether exposure continued from childhood. Occupational questions should name jobs and agents: silica or stone dust, coal, welding fumes, textile or grain dust, diesel exhaust and chemical vapours. Personal protective equipment does not erase exposure and should not replace workplace control.
Lung development influences later reserve. Prematurity, low birth weight, childhood respiratory infection, undernutrition and longstanding asthma may lead to a lower attained peak lung function. Previous pulmonary tuberculosis can leave bronchiectasis, fibrosis, cavities or mixed obstruction and restriction. HIV, recurrent infection and socioeconomic barriers may modify this pathway. Consider alpha-1 antitrypsin deficiency when emphysema is early, disproportionate, basilar, familial or accompanied by liver disease; local access to testing varies.
Exacerbation risk rises most reliably with prior exacerbations. Low FEV1, continued smoke exposure, poor inhaler technique, bronchiectasis, chronic mucus, frailty and comorbid heart disease can add risk. Review medicines that impair respiration or complicate treatment, including sedatives and non-selective beta-blockade, without stopping essential therapy abruptly. Cardiovascular disease, osteoporosis, anxiety, depression, malnutrition, obesity, lung cancer and sleep-disordered breathing are not side notes: they alter symptoms, safety and prognosis and require active case finding.
Diagnosis
History
Establish the symptom pattern, tempo and functional consequence. Ask about exertional breathlessness, cough, sputum volume or purulence, wheeze, chest tightness, fatigue, weight change and activity avoided. Count treated exacerbations, emergency visits and admissions over the preceding year, especially events requiring hospitalisation. Document tobacco, household fuel, occupational dust or fume exposure, childhood disease, asthma, tuberculosis and family lung or liver disease. Variability, nocturnal waking, atopy or a large treatment response may favour asthma; haemoptysis, fever, night sweats or rapid weight loss demands investigation for TB, infection or cancer.
Examination
Record respiratory rate, pulse, blood pressure, temperature, oxygen saturation, body mass index and ability to speak and mobilise. Hyperinflation, prolonged expiration, quiet breath sounds and wheeze support airflow obstruction but a normal examination does not exclude COPD. Crackles, clubbing, focal signs, lymphadenopathy or marked asymmetry suggest another or additional diagnosis. Look for cyanosis, accessory-muscle use, asterixis or altered mentation in possible respiratory failure. Assess oedema, jugular venous pressure and cardiac findings, muscle mass, gait, mood, oral health and the practical ability to operate the prescribed inhaler.
Investigations
Confirm stable disease with acceptable, reproducible post-bronchodilator spirometry: GOLD uses FEV1/FVC below 0.70. Repeat a borderline result and interpret age and lower-limit-of-normal context; do not diagnose during an unstable exacerbation from a single poor tracing. Chest radiography, blood count and BMI help detect alternatives or complications. Select ECG, echocardiography, CT, diffusing capacity, sputum microbiology, TB testing, alpha-1 antitrypsin testing and exercise or sleep assessment according to the presentation. Blood eosinophils inform the probability of benefit from adding inhaled corticosteroid; they do not diagnose COPD or replace exacerbation history.
Differential Diagnosis
Asthma is suggested by childhood or early onset, atopy, substantial day-to-day variability and symptoms that improve markedly, but asthma and COPD can coexist. In that situation, do not withdraw necessary inhaled corticosteroid merely to force the patient into one label. Bronchiectasis causes recurrent infection, larger-volume purulent sputum and haemoptysis; high-resolution CT confirms abnormal bronchial dilatation. Post-tuberculosis lung disease may produce obstruction, restriction or both. Active TB remains possible with cough, constitutional symptoms, haemoptysis or new radiographic change and requires microbiological evaluation through appropriate pathways.
Heart failure can mimic COPD with exertional dyspnoea and even wheeze. Orthopnoea, paroxysmal nocturnal dyspnoea, oedema, raised jugular venous pressure, ECG or radiographic abnormalities and natriuretic peptides guide further assessment. Anaemia, obesity, deconditioning, pulmonary hypertension and sleep apnoea can magnify otherwise modest spirometric disease. Interstitial lung disease is suggested by fine inspiratory crackles, clubbing, restriction or characteristic CT change.
Lung cancer, pulmonary embolism, pleural disease and pneumothorax should not be missed when symptoms are focal, sudden or disproportionate. Upper-airway obstruction may flatten a flow-volume loop. Bronchiolitis, obliterative small-airway disease and occupational lung disease require specialist reasoning. A chest CT showing emphysema does not by itself establish symptomatic COPD, and chronic cough without obstruction may be chronic bronchitis, upper-airway cough syndrome, reflux or medication related. Revisit the diagnosis when treatment fails rather than layering more inhalers onto uncertainty.
Management
Begin with a shared account of what limits the person: breathlessness, exacerbations, work, sleep, travel or fear. Help all tobacco users quit with behavioural support and locally appropriate pharmacotherapy. Reduce second-hand smoke, cooking smoke and occupational exposure through feasible environmental and workplace changes. Recommend physical activity, nutrition support when underweight, relevant vaccination and a written self-management plan. Pulmonary rehabilitation is high-value for persistent limitation and after suitable exacerbations, but availability and transport can be barriers; home-supported alternatives should preserve assessment and exercise safety.
After confirmation, a short-acting bronchodilator can relieve intermittent symptoms. GOLD's A, B and E grouping uses symptom burden and recent exacerbations to guide initial long-acting therapy. A long-acting bronchodilator may suit lower symptom burden; dual LABA/LAMA is commonly preferred when symptoms are substantial or exacerbation risk is high. Review response through breathlessness, activity and events, not FEV1 alone. Before escalation, check diagnosis, adherence, inhaler technique, device suitability, exposure and comorbidity.
ICS is added selectively, principally for exacerbation prevention when eosinophils and event history predict benefit or when asthma coexists. The eosinophil count is a continuum: benefit is usually unlikely below about 100 cells per microlitre and more likely around or above 300, while repeated values and clinical context matter. Discuss pneumonia, oral candidiasis, dysphonia, bruising and systemic exposure. Consider roflumilast, macrolide prevention, lung-volume intervention or transplantation only after specialist phenotyping. Treat anxiety, depression, cardiovascular risk, osteoporosis and frailty, and introduce breathlessness palliation and future-care planning before crisis.
Prescribing Information
Choose a device the person can load, seal around, actuate and inhale correctly. Inspiratory flow, hand strength, coordination, cognition, vision, cost and refill availability can matter more than theoretical device preference. Demonstrate, observe teach-back and recheck technique at every escalation. A spacer can improve delivery from a pressurised metered-dose inhaler. Do not assume a nebuliser is stronger; it adds cleaning, power and contamination burdens and should continue only when it produces documented benefit. Avoid duplicate LABA or LAMA ingredients hidden across combination inhalers.
Bronchodilators can cause tremor, palpitations, dry mouth or urinary symptoms. Antimuscarinic therapy needs caution with urinary retention and some glaucoma contexts; beta-agonists require attention to tachyarrhythmia and potassium in vulnerable patients. ICS should not be used as monotherapy for COPD. Rinse the mouth after an ICS-containing inhaler, review pneumonia history and reconsider the indication after adverse effects. Long-term oral corticosteroids usually cause more harm than benefit in stable COPD. Methylxanthines have interactions and a narrow therapeutic margin and are not a casual substitute for unavailable inhalers.
During an exacerbation, increase short-acting bronchodilation, provide a short systemic corticosteroid course when indicated, and reserve antibiotics for clinical features suggesting bacterial infection or when ventilation is required, following local antimicrobial guidance. Oxygen is prescribed to a target; people at risk of hypercapnic failure commonly need controlled oxygen and blood-gas reassessment rather than unrestricted flow. Long-term oxygen requires stable assessment and arterial-gas criteria. Opioids for refractory breathlessness belong to individualized palliative practice with careful titration and monitoring, not unsupervised self-medication.
When to Refer
Refer for respiratory assessment when the diagnosis is uncertain, spirometry is discordant with symptoms, onset is young, decline is rapid, alpha-1 antitrypsin deficiency is suspected or asthma, bronchiectasis, post-TB disease, interstitial disease or malignancy may coexist. Specialist help is also appropriate for frequent exacerbations despite optimized basics, hospital admission, haemoptysis, chronic purulent sputum, cor pulmonale, disproportionate hypoxaemia, hypercapnia, unintentional weight loss or consideration of roflumilast, prophylactic antibiotic, home ventilation, lung-volume procedure or transplant.
Pulmonary rehabilitation referral should not wait for very severe spirometry when exertional limitation is meaningful. Refer to tobacco-cessation, physiotherapy, dietetic, mental-health, occupational-health and palliative services according to need. Oxygen assessment requires stability, optimized treatment and gas measurement; a low spot oximeter reading during infection is not an automatic lifetime prescription. After an admission, ensure early review of recovery, inhalers, oxygen, steroid and antibiotic stop dates, rehabilitation and an action plan.
Emergency transfer is required for severe or rapidly worsening breathlessness, inability to speak, exhaustion, confusion, cyanosis, haemodynamic instability, new focal chest pain, silent chest, suspected pneumothorax, significant haemoptysis or poor response to initial therapy. Persistent acidotic hypercapnic ventilatory failure despite optimal medical treatment is an indication for non-invasive ventilation in a trained setting. If NIV fails or is inappropriate, escalation to invasive ventilation depends on reversibility, function, comorbidity, patient wishes and agreed ceilings, not age or FEV1 alone.
Red Flags
An apparent COPD exacerbation is a syndrome, not a final cause. Seek pneumonia, pneumothorax, pulmonary embolism, acute coronary syndrome, arrhythmia and heart failure when deterioration is abrupt, painful, febrile, focal or disproportionate. New haemoptysis, persistent focal radiographic change, progressive hoarseness, lymphadenopathy or weight loss raises concern for cancer or TB. In an Indian setting, prolonged cough, fever, night sweats, close TB exposure or new cavitation requires prompt TB testing and infection-control attention rather than repeated empirical antibiotics.
Signs of life-threatening respiratory failure include confusion, drowsiness, agitation, asterixis, exhaustion, paradoxical breathing, poor air entry, cyanosis, hypotension and worsening acidosis. Pulse oximetry does not reveal carbon dioxide or pH. Give controlled oxygen without withholding oxygen from a critically hypoxaemic patient, obtain blood gases where indicated and reassess after any oxygen change. NIV must have trained monitoring and a documented plan if physiology deteriorates.
Medication hazards include repeated unsupervised steroid courses, prolonged antibiotics, sedative or opioid accumulation, theophylline toxicity and duplicate long-acting bronchodilators. Sudden stopping of chronic systemic steroids can be dangerous. A falling eosinophil count during systemic steroid use is not a reliable untreated baseline. At home, fire risk makes smoking around oxygen an emergency safety problem. Recurrent falls, inability to eat, caregiver exhaustion, panic, depression or expressed hopelessness also demand action; severe COPD care is unsafe when psychosocial red flags are treated as less real than blood-gas abnormalities.
Indian Clinical Context
India does not have one COPD phenotype or one uniform delivery system. Ask about bidis as well as cigarettes, and about cooking arrangements rather than simply recording 'non-smoker'. Biomass exposure may be shared by women, children and older relatives, and cleaner-fuel access does not guarantee continued use if refill cost, cooking preference or supply is difficult. Exposure reduction should be practical and non-blaming. Outdoor pollution advice must not imply that an individual can solve a structural problem; focus on reliable local alerts and feasible reduction during severe episodes without promoting unproven masks or indoor devices.
Prior TB can leave obstruction, fibrosis and bronchiectasis, while active TB can resemble an exacerbation. Determine whether old treatment was completed, whether microbiology was documented and whether imaging has changed. Do not restart anti-tuberculosis drugs empirically from an old prescription. Use NTEP-linked diagnostic routes when active disease is suspected. Occupational histories matter in quarrying, mining, construction, welding, textiles and agriculture; documentation may support exposure control and compensation processes.
Access shapes the plan. A dry-powder device is not useful if inspiratory flow is inadequate; a once-daily combination is not effective if unaffordable; rehabilitation cannot work if travel consumes a day's wages. List generic drug classes, demonstrate the exact available device and provide an affordable contingency. NIV, arterial blood gases, CT, eosinophil counts and transplant evaluation are not uniformly available. international and GOLD inform principles but do not create an Indian national formulary or referral guarantee. Record the actual facility, oxygen supplier, follow-up route and emergency plan.
NMC Competency Mapping
The 2024 NMC undergraduate curriculum places obstructive airway disease in General Medicine topic GM28. Relevant knowledge outcomes include defining and classifying obstructive airway disease (GM28.1), epidemiology and risk (GM28.2), acute precipitants (GM28.3), hypoxia and hypercapnia (GM28.4), alpha-1 antitrypsin deficiency (GM28.5) and environmental causes (GM28.6). Clinical learners should elicit and present a differentiating history under GM28.8 and formulate an appropriate diagnostic work-up under GM28.13.
Therapeutic mapping includes bronchodilators, steroids, oxygen and other airway therapies under GM28.15; vaccination under GM28.16; an individualized bronchodilator and inhaled-corticosteroid plan under GM28.17; management of acute exacerbations under GM28.18; and hospital and home oxygen principles under GM28.19. Communication and skills are explicit: GM28.20 covers smoking-cessation counselling, GM28.21 correct inhaler use and GM28.22 communication of diagnosis, treatment and follow-up. GM28.23 to GM28.26 address quality of life and the constraints that living, work and smoking dependence place on behaviour.
Physiology competency PY6.10 requires performance and interpretation of spirometry, while pharmacology PH5.1 covers management and drug effects in asthma and COPD. These mappings define learning outcomes, not independent clinical authority. Device teaching and spirometry require direct observation, calibration and supervised practice. The guide deliberately uses NMC's broader obstructive-airway framing while explaining COPD-specific evidence from GOLD and international guidelines; exam candidates should not substitute a remembered code for clinical confirmation or patient-centred reasoning.
Key Exam Pearls for NEET PG
COPD requires compatible exposure and symptoms plus persistent post-bronchodilator airflow obstruction; radiographic hyperinflation or a smoking history alone is insufficient. GOLD uses post-bronchodilator FEV1/FVC below 0.70, but borderline results need quality review and age-aware interpretation. FEV1 grade describes obstruction, whereas symptom tools and the previous year's exacerbations drive the A, B and E clinical grouping. The strongest predictor of a future exacerbation is a previous exacerbation.
Initial treatment prioritises long-acting bronchodilation. LABA/LAMA generally improves breathlessness more than simply adding ICS. ICS is for selected exacerbation-prone or asthma-overlap phenotypes; blood eosinophils estimate response probability and are not a diagnostic test. A count below about 100 cells per microlitre predicts little average ICS benefit, while around or above 300 predicts a higher likelihood, interpreted with repeated results and pneumonia risk. Stable COPD does not justify chronic oral steroids. Smoking cessation, vaccination, pulmonary rehabilitation, physical activity and device mastery are core treatment, not optional counselling.
An exacerbation is an acute worsening over usual variability, but always test the mimic: pneumonia, PE, pneumothorax, heart failure or ACS. In hypercapnia risk, prescribe controlled oxygen, often targeting 88-92% while blood gases guide adjustment. Persistent acidotic hypercapnic failure despite optimal therapy favours NIV. Long-term oxygen is for verified stable severe hypoxaemia, not breathlessness with normal oxygenation. Cor pulmonale, cachexia, recurrent admission and refractory breathlessness prompt specialist and palliative input; palliation can coexist with rehabilitation, NIV assessment and active disease treatment.
Frequently Asked Questions
Can COPD be diagnosed from symptoms, a chest radiograph or a smoking history alone?
No. Those features can raise suspicion, but stable COPD requires technically acceptable post-bronchodilator spirometry interpreted in clinical context. Hyperinflation or emphysema on imaging can support phenotyping and reveal alternatives, but neither replaces airflow measurement. A borderline ratio should be repeated and considered against age, test quality and the lower limit of normal.
Does every person with COPD need an inhaled corticosteroid-containing inhaler?
No. Long-acting bronchodilators are the foundation for most symptomatic patients. An inhaled corticosteroid is considered mainly when exacerbation history, blood eosinophils or coexisting asthma predict benefit. Pneumonia and local adverse effects must be discussed, and technique, adherence, exposure and alternative causes of deterioration should be corrected before escalation.
Why must tuberculosis and household smoke be considered in Indian COPD assessment?
Household solid-fuel smoke can produce long cumulative exposure even in a person who never smoked tobacco. Previous pulmonary TB may leave bronchiectasis, fibrosis or mixed ventilatory defects, while active TB can mimic an exacerbation with cough, weight loss or haemoptysis. These possibilities change investigations, infection control and treatment, so they should not be hidden inside a generic COPD label.
When does a COPD exacerbation require urgent ventilatory assessment rather than more inhalers at home?
Urgent assessment is needed for severe or rapidly worsening breathlessness, inability to speak, exhaustion, confusion, cyanosis, haemodynamic instability, poor air entry or failure to respond to the action plan. Blood gases are essential when hypercapnic failure is possible. Persistent acidotic hypercapnic ventilatory failure despite optimal medical treatment is a standard indication for monitored non-invasive ventilation.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic